AU2004285013A1 - A2B adenosine receptor antagonists - Google Patents
A2B adenosine receptor antagonists Download PDFInfo
- Publication number
- AU2004285013A1 AU2004285013A1 AU2004285013A AU2004285013A AU2004285013A1 AU 2004285013 A1 AU2004285013 A1 AU 2004285013A1 AU 2004285013 A AU2004285013 A AU 2004285013A AU 2004285013 A AU2004285013 A AU 2004285013A AU 2004285013 A1 AU2004285013 A1 AU 2004285013A1
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- dione
- nitro
- compound
- dihydropyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940121359 adenosine receptor antagonist Drugs 0.000 title abstract description 7
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title abstract description 7
- 101150078577 Adora2b gene Proteins 0.000 title description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 155
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 73
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
- 239000001257 hydrogen Substances 0.000 claims abstract description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 34
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract description 25
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 208000035475 disorder Diseases 0.000 claims abstract description 15
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims abstract description 14
- 208000019693 Lung disease Diseases 0.000 claims abstract description 13
- 208000006673 asthma Diseases 0.000 claims abstract description 11
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 7
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 6
- 230000001900 immune effect Effects 0.000 claims abstract description 6
- 208000026278 immune system disease Diseases 0.000 claims abstract description 6
- 230000033115 angiogenesis Effects 0.000 claims abstract description 5
- 230000001684 chronic effect Effects 0.000 claims abstract description 5
- 230000000414 obstructive effect Effects 0.000 claims abstract description 5
- 206010014561 Emphysema Diseases 0.000 claims abstract description 4
- 206010035664 Pneumonia Diseases 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 71
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 125000001424 substituent group Chemical group 0.000 claims description 57
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108050000203 Adenosine receptors Proteins 0.000 claims description 6
- 102000009346 Adenosine receptors Human genes 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Chemical group 0.000 claims description 6
- 229910052717 sulfur Chemical group 0.000 claims description 6
- 239000011593 sulfur Chemical group 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- BLXPWHRRRAJSPY-UHFFFAOYSA-N 1h-pyrrolo[3,2-d]pyrimidine-2,6-dione Chemical compound N1C(=O)N=CC2=NC(=O)C=C21 BLXPWHRRRAJSPY-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract description 12
- -1 n-decyl Chemical group 0.000 description 99
- 239000000203 mixture Substances 0.000 description 48
- 125000003118 aryl group Chemical group 0.000 description 46
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 41
- 238000002360 preparation method Methods 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 28
- 239000004480 active ingredient Substances 0.000 description 26
- 125000003545 alkoxy group Chemical group 0.000 description 26
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 229910052736 halogen Inorganic materials 0.000 description 23
- 150000002367 halogens Chemical class 0.000 description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 22
- 125000004181 carboxyalkyl group Chemical group 0.000 description 22
- 125000004093 cyano group Chemical group *C#N 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 22
- 239000004615 ingredient Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 150000001412 amines Chemical class 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 125000000623 heterocyclic group Chemical group 0.000 description 19
- 239000003826 tablet Substances 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 125000000392 cycloalkenyl group Chemical group 0.000 description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 15
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 14
- 229960005305 adenosine Drugs 0.000 description 14
- 125000002947 alkylene group Chemical group 0.000 description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- WRWQSJUSHNWSNL-UHFFFAOYSA-N 6-methyl-5-nitro-1,3-dipropylpyrimidine-2,4-dione Chemical compound CCCN1C(C)=C([N+]([O-])=O)C(=O)N(CCC)C1=O WRWQSJUSHNWSNL-UHFFFAOYSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- ZTGWXXOUUKHQLW-UHFFFAOYSA-N 1-nitropyrimidine-2,4-dione Chemical compound [O-][N+](=O)N1C=CC(=O)NC1=O ZTGWXXOUUKHQLW-UHFFFAOYSA-N 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 229930194542 Keto Natural products 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 125000004423 acyloxy group Chemical group 0.000 description 9
- 125000005110 aryl thio group Chemical group 0.000 description 9
- 125000004104 aryloxy group Chemical group 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 125000005553 heteroaryloxy group Chemical group 0.000 description 9
- 125000000468 ketone group Chemical group 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 125000000033 alkoxyamino group Chemical group 0.000 description 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 8
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 125000005368 heteroarylthio group Chemical group 0.000 description 8
- 125000004470 heterocyclooxy group Chemical group 0.000 description 8
- 229910017604 nitric acid Inorganic materials 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 229940093499 ethyl acetate Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 125000004468 heterocyclylthio group Chemical group 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000019256 formaldehyde Nutrition 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 229930195734 saturated hydrocarbon Natural products 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 125000005017 substituted alkenyl group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 101150046889 ADORA3 gene Proteins 0.000 description 4
- 101150051188 Adora2a gene Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000001593 cAMP accumulation Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WOXHPHOZJMLUFE-UHFFFAOYSA-N 1-benzylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C=NN1CC1=CC=CC=C1 WOXHPHOZJMLUFE-UHFFFAOYSA-N 0.000 description 3
- OWAHOYKKKIEKPM-UHFFFAOYSA-N 1-ethyl-6-methyl-5-nitro-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C([N+]([O-])=O)=C(C)N(CC)C1=O OWAHOYKKKIEKPM-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- CVTDHCYRKGQTOT-UHFFFAOYSA-N 6-methyl-1,3-dipropylpyrimidine-2,4-dione Chemical compound CCCN1C(C)=CC(=O)N(CCC)C1=O CVTDHCYRKGQTOT-UHFFFAOYSA-N 0.000 description 3
- BBFJPUDLETXJCY-UHFFFAOYSA-N 6-methyl-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(C)NC1=O BBFJPUDLETXJCY-UHFFFAOYSA-N 0.000 description 3
- CZRQKJMIOGNEIQ-UHFFFAOYSA-N 6-methyl-5-nitro-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)NC(C)=C([N+]([O-])=O)C1=O CZRQKJMIOGNEIQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 125000005549 heteroarylene group Chemical group 0.000 description 3
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- HJPOQNKXQHXEKE-UHFFFAOYSA-N (1-benzylpyrazol-4-yl)methanol Chemical compound C1=C(CO)C=NN1CC1=CC=CC=C1 HJPOQNKXQHXEKE-UHFFFAOYSA-N 0.000 description 2
- KTKDYVVUGTXLJK-UHFFFAOYSA-N 1,1-dipropylurea Chemical compound CCCN(C(N)=O)CCC KTKDYVVUGTXLJK-UHFFFAOYSA-N 0.000 description 2
- ZJONPIRNUOSPQW-UHFFFAOYSA-N 1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carbaldehyde Chemical compound FC(F)(F)C1=CC=CC(CN2N=CC(C=O)=C2)=C1 ZJONPIRNUOSPQW-UHFFFAOYSA-N 0.000 description 2
- PXCDSZCZMQXGLT-UHFFFAOYSA-N 1-[[4-(trifluoromethyl)phenyl]methyl]-5H-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1C(=O)NC(=O)C2=C1C=CN2 PXCDSZCZMQXGLT-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BXIGAOOEYIYEFN-UHFFFAOYSA-N 3-ethyl-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound CCN1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O BXIGAOOEYIYEFN-UHFFFAOYSA-N 0.000 description 2
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 2
- IVDXTRMSPBIIFM-UHFFFAOYSA-N 5-nitro-1-[[4-(trifluoromethyl)phenyl]methyl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C([N+](=O)[O-])=CN1CC1=CC=C(C(F)(F)F)C=C1 IVDXTRMSPBIIFM-UHFFFAOYSA-N 0.000 description 2
- TUARVSWVPPVUGS-UHFFFAOYSA-N 5-nitrouracil Chemical compound [O-][N+](=O)C1=CNC(=O)NC1=O TUARVSWVPPVUGS-UHFFFAOYSA-N 0.000 description 2
- SHVCSCWHWMSGTE-UHFFFAOYSA-N 6-methyluracil Chemical compound CC1=CC(=O)NC(=O)N1 SHVCSCWHWMSGTE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 101150007969 ADORA1 gene Proteins 0.000 description 2
- 102000007470 Adenosine A2B Receptor Human genes 0.000 description 2
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- MVOLUQHIASOMOM-UHFFFAOYSA-N [1-[(4-methylphenyl)methyl]pyrazol-4-yl]methanol Chemical compound C1=CC(C)=CC=C1CN1N=CC(CO)=C1 MVOLUQHIASOMOM-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CUTDJCLKKQWXGM-UHFFFAOYSA-N ethyl 1-benzylpyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC=C1 CUTDJCLKKQWXGM-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000005156 substituted alkylene group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- QSXREDPBMQKKAY-UHFFFAOYSA-N (1-methylpyrazol-4-yl)methanol Chemical compound CN1C=C(CO)C=N1 QSXREDPBMQKKAY-UHFFFAOYSA-N 0.000 description 1
- UCPVQFRIXFGLOJ-UHFFFAOYSA-N (1-phenylpyrazol-4-yl)methanol Chemical compound C1=C(CO)C=NN1C1=CC=CC=C1 UCPVQFRIXFGLOJ-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- GUBGKLYUXWCFEA-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound O=C1N(CCOC)C(=O)N(CCOC)C(C2=CN(N=C2)C=2C=CC=CC=2)=C1[N+]([O-])=O GUBGKLYUXWCFEA-UHFFFAOYSA-N 0.000 description 1
- RFGJNFGWCQGRTM-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CCOC)C(=O)N(CCOC)C(C2=CN(C)N=C2)=C1[N+]([O-])=O RFGJNFGWCQGRTM-UHFFFAOYSA-N 0.000 description 1
- IKOHXEGDOSIHSW-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound COCCN1C(C)=C([N+]([O-])=O)C(=O)N(CCOC)C1=O IKOHXEGDOSIHSW-UHFFFAOYSA-N 0.000 description 1
- NWZHMVZQTCBMTB-UHFFFAOYSA-N 1,3-bis(2-methoxyethyl)-6-methylpyrimidine-2,4-dione Chemical compound COCCN1C(C)=CC(=O)N(CCOC)C1=O NWZHMVZQTCBMTB-UHFFFAOYSA-N 0.000 description 1
- FKSAQKOKBWGJLU-UHFFFAOYSA-N 1,3-bis(2-methylpropyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CC(C)C)C(C2=CN(C)N=C2)=C1[N+]([O-])=O FKSAQKOKBWGJLU-UHFFFAOYSA-N 0.000 description 1
- YPJYCXBZLFQBTL-UHFFFAOYSA-N 1,3-bis(2-methylpropyl)-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CC(C)C)C=2C=C1C=1C=NN(C)C=1 YPJYCXBZLFQBTL-UHFFFAOYSA-N 0.000 description 1
- BAIYZJVFQVIJBI-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)CC2=COC=C2)=C([N+]([O-])=O)C(=O)N1CC1=COC=C1 BAIYZJVFQVIJBI-UHFFFAOYSA-N 0.000 description 1
- VZCUIIVGPFMKTR-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC2=COC=C2)C(C)=C([N+]([O-])=O)C(=O)N1CC=1C=COC=1 VZCUIIVGPFMKTR-UHFFFAOYSA-N 0.000 description 1
- IGBXFKSOOYXPDT-UHFFFAOYSA-N 1,3-bis(furan-3-ylmethyl)-6-methylpyrimidine-2,4-dione Chemical compound O=C1N(CC2=COC=C2)C(C)=CC(=O)N1CC=1C=COC=1 IGBXFKSOOYXPDT-UHFFFAOYSA-N 0.000 description 1
- KYKRBKPQIAMDEF-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound COC1=CC=C(CN2C(N(C(C(=C2)[N+](=O)[O-])=O)CC2=CC=C(C=C2)OC)=O)C=C1 KYKRBKPQIAMDEF-UHFFFAOYSA-N 0.000 description 1
- VYYOIZHXYZPJBS-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(C)N=C1 VYYOIZHXYZPJBS-UHFFFAOYSA-N 0.000 description 1
- QQXQPOMHCZPKFR-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C([N+]([O-])=O)=C1C QQXQPOMHCZPKFR-UHFFFAOYSA-N 0.000 description 1
- FAIVXHBWPVXWAW-UHFFFAOYSA-N 1,3-bis[(4-methoxyphenyl)methyl]-6-methylpyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C=C1C FAIVXHBWPVXWAW-UHFFFAOYSA-N 0.000 description 1
- FVKBVEXRIGSLAW-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C=1C=CC=CC=1C(F)N1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1C1=CC=CC=C1 FVKBVEXRIGSLAW-UHFFFAOYSA-N 0.000 description 1
- ORKRTXKUSDMMPU-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound C1=NN(C)C=C1C(N(C1=O)C(F)C=2C=CC=CC=2)=C([N+]([O-])=O)C(=O)N1C(F)C1=CC=CC=C1 ORKRTXKUSDMMPU-UHFFFAOYSA-N 0.000 description 1
- PUTBUVMEDUJKGN-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(CC=4C(=CC=CC=4)F)N=C3)NC=2C(=O)N(C(F)C=2C=CC=CC=2)C(=O)N1C(F)C1=CC=CC=C1 PUTBUVMEDUJKGN-UHFFFAOYSA-N 0.000 description 1
- GJVPZLCBQJUGIN-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(C(F)C=2C=CC=CC=2)C(C)=C([N+]([O-])=O)C(=O)N1C(F)C1=CC=CC=C1 GJVPZLCBQJUGIN-UHFFFAOYSA-N 0.000 description 1
- VEPRCCJEIDFZPZ-UHFFFAOYSA-N 1,3-bis[fluoro(phenyl)methyl]-6-methylpyrimidine-2,4-dione Chemical compound O=C1N(C(F)C=2C=CC=CC=2)C(C)=CC(=O)N1C(F)C1=CC=CC=C1 VEPRCCJEIDFZPZ-UHFFFAOYSA-N 0.000 description 1
- JKVRFTLOCLVZIL-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(C2CCC2)C(C)=C([N+]([O-])=O)C(=O)N1C1CCC1 JKVRFTLOCLVZIL-UHFFFAOYSA-N 0.000 description 1
- GNJVRMFBYCSMTF-UHFFFAOYSA-N 1,3-di(cyclobutyl)-6-methylpyrimidine-2,4-dione Chemical compound O=C1N(C2CCC2)C(C)=CC(=O)N1C1CCC1 GNJVRMFBYCSMTF-UHFFFAOYSA-N 0.000 description 1
- NEOPMLYYUWCGAK-UHFFFAOYSA-N 1,3-dibutyl-6-(1-methylpyrazol-4-yl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C(C2=CN(C)N=C2)=C1[N+]([O-])=O NEOPMLYYUWCGAK-UHFFFAOYSA-N 0.000 description 1
- LTOXYPBYEIEWNO-UHFFFAOYSA-N 1,3-dibutyl-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2C=C1C=1C=NN(C)C=1 LTOXYPBYEIEWNO-UHFFFAOYSA-N 0.000 description 1
- PBWSWPPSIGNRRD-UHFFFAOYSA-N 1,3-dibutyl-6-(1-phenylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2C=C1C(=C1)C=NN1C1=CC=CC=C1 PBWSWPPSIGNRRD-UHFFFAOYSA-N 0.000 description 1
- PUTINCZBICECNT-UHFFFAOYSA-N 1,3-dibutyl-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(C)=C([N+]([O-])=O)C(=O)N(CCCC)C1=O PUTINCZBICECNT-UHFFFAOYSA-N 0.000 description 1
- PULKYJIQBKJPOQ-UHFFFAOYSA-N 1,3-dibutyl-6-methylpyrimidine-2,4-dione Chemical compound CCCCN1C(C)=CC(=O)N(CCCC)C1=O PULKYJIQBKJPOQ-UHFFFAOYSA-N 0.000 description 1
- UXHBUITXGQEESD-UHFFFAOYSA-N 1,3-diethyl-6-(1-methylpyrazol-4-yl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2C=C1C=1C=NN(C)C=1 UXHBUITXGQEESD-UHFFFAOYSA-N 0.000 description 1
- DQAWDNPKOKNXLO-UHFFFAOYSA-N 1,3-diethyl-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound CCN1C(C)=C([N+]([O-])=O)C(=O)N(CC)C1=O DQAWDNPKOKNXLO-UHFFFAOYSA-N 0.000 description 1
- VOUHTHBOMCQORO-UHFFFAOYSA-N 1,3-diethyl-6-methylpyrimidine-2,4-dione Chemical compound CCN1C(C)=CC(=O)N(CC)C1=O VOUHTHBOMCQORO-UHFFFAOYSA-N 0.000 description 1
- LWDDPJKYTDZXKY-UHFFFAOYSA-N 1,3-dipropyl-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound O=C1N(CCC)C(=O)N(CCC)C2=C1NC=C2 LWDDPJKYTDZXKY-UHFFFAOYSA-N 0.000 description 1
- OTTXHVDIBKLLRP-UHFFFAOYSA-N 1,6-dimethyl-3-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O OTTXHVDIBKLLRP-UHFFFAOYSA-N 0.000 description 1
- SFJJJHPKTFEOFJ-UHFFFAOYSA-N 1,6-dimethyl-5-nitro-3-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(C)C(C)=C([N+]([O-])=O)C(=O)N1CCC1=CC=CC=C1 SFJJJHPKTFEOFJ-UHFFFAOYSA-N 0.000 description 1
- JESJDAQRWZBLPS-UHFFFAOYSA-N 1,6-dimethyl-5-nitro-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(C)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 JESJDAQRWZBLPS-UHFFFAOYSA-N 0.000 description 1
- SSHLQZVARPPYCO-UHFFFAOYSA-N 1-(2-methylpropyl)-3-propyl-6-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC(C)C)C=2C=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 SSHLQZVARPPYCO-UHFFFAOYSA-N 0.000 description 1
- KGGDHDNKOKFRTL-UHFFFAOYSA-N 1-(2-methylpropyl)-5-nitro-3-(2-phenylethyl)-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound [O-][N+](=O)C=1C(=O)N(CCC=2C=CC=CC=2)C(=O)N(CC(C)C)C=1C(=C1)C=NN1C1=CC=CC=C1 KGGDHDNKOKFRTL-UHFFFAOYSA-N 0.000 description 1
- MNTBDJMKEQNLMO-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-methyl-5-nitro-3-propylpyrimidine-2,4-dione Chemical compound O=C1N(CCC)C(=O)C([N+]([O-])=O)=C(C)N1CC1CC1 MNTBDJMKEQNLMO-UHFFFAOYSA-N 0.000 description 1
- SAAZLZSKXMIFTA-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-5-nitro-6-(1-phenylpyrazol-4-yl)pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC2=COC=C2)C(C2=CN(N=C2)C=2C=CC=CC=2)=C([N+]([O-])=O)C1=O SAAZLZSKXMIFTA-UHFFFAOYSA-N 0.000 description 1
- CBGFILJGDMSSPB-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC2=COC=C2)C(C)=C([N+]([O-])=O)C1=O CBGFILJGDMSSPB-UHFFFAOYSA-N 0.000 description 1
- OUKQTRFCDKSEPL-UHFFFAOYSA-N 1-Methyl-2-pyrrolecarboxaldehyde Chemical compound CN1C=CC=C1C=O OUKQTRFCDKSEPL-UHFFFAOYSA-N 0.000 description 1
- KRZNCRHCJCDMPQ-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]pyrazole-4-carbaldehyde Chemical compound FC1=CC=CC=C1CN1N=CC(C=O)=C1 KRZNCRHCJCDMPQ-UHFFFAOYSA-N 0.000 description 1
- LQOMVXFGKOPRBF-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]pyrazole-4-carbaldehyde Chemical compound COC1=CC=CC(CN2N=CC(C=O)=C2)=C1 LQOMVXFGKOPRBF-UHFFFAOYSA-N 0.000 description 1
- RVSRSMWMTFWNOX-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]pyrazole-4-carbaldehyde Chemical compound C1=CC(C)=CC=C1CN1N=CC(C=O)=C1 RVSRSMWMTFWNOX-UHFFFAOYSA-N 0.000 description 1
- QZSPXAXZMWZHNB-UHFFFAOYSA-N 1-[fluoro(phenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound FC(C1=CC=CC=C1)N1C(NC(C(=C1)[N+](=O)[O-])=O)=O QZSPXAXZMWZHNB-UHFFFAOYSA-N 0.000 description 1
- NAEVUHMPXSVZBD-UHFFFAOYSA-N 1-butyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CCCC)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C1[N+]([O-])=O NAEVUHMPXSVZBD-UHFFFAOYSA-N 0.000 description 1
- WAOQUAIDCGKMOW-UHFFFAOYSA-N 1-butyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(2-methylpropyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CCCC)C=2C=C1C(=C1)C=NN1CC1=CC=CC=C1F WAOQUAIDCGKMOW-UHFFFAOYSA-N 0.000 description 1
- INKWSLVWTNYBRO-UHFFFAOYSA-N 1-butyl-6-methyl-3-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(C)=C([N+]([O-])=O)C(=O)N(CC(C)C)C1=O INKWSLVWTNYBRO-UHFFFAOYSA-N 0.000 description 1
- ISMPWQDJSKZSIS-UHFFFAOYSA-N 1-cyclobutyl-6-methyl-5-nitro-3-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(C2CCC2)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 ISMPWQDJSKZSIS-UHFFFAOYSA-N 0.000 description 1
- SWMNHYUCMMFTIE-UHFFFAOYSA-N 1-cyclopropyl-3,5,6-trimethyl-5-nitro-1,3-diazinane-2,4-dione Chemical compound O=C1N(C)C(=O)C([N+]([O-])=O)(C)C(C)N1C1CC1 SWMNHYUCMMFTIE-UHFFFAOYSA-N 0.000 description 1
- SDFUDIQOLCLBLH-UHFFFAOYSA-N 1-cyclopropyl-3-(furan-3-ylmethyl)-5,6-dimethyl-5-nitro-1,3-diazinane-2,4-dione Chemical compound O=C1N(CC2=COC=C2)C(=O)C([N+]([O-])=O)(C)C(C)N1C1CC1 SDFUDIQOLCLBLH-UHFFFAOYSA-N 0.000 description 1
- HYKTXNMLFVLPDT-UHFFFAOYSA-N 1-cyclopropyl-3-[(4-fluorophenyl)methyl]-5,6-dimethyl-5-nitro-1,3-diazinane-2,4-dione Chemical compound O=C1N(CC=2C=CC(F)=CC=2)C(=O)C([N+]([O-])=O)(C)C(C)N1C1CC1 HYKTXNMLFVLPDT-UHFFFAOYSA-N 0.000 description 1
- FQMDCQAEEVCOBZ-UHFFFAOYSA-N 1-cyclopropyl-3-[(4-methoxyphenyl)methyl]-5,6-dimethyl-5-nitro-1,3-diazinane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(C)([N+]([O-])=O)C(C)N(C2CC2)C1=O FQMDCQAEEVCOBZ-UHFFFAOYSA-N 0.000 description 1
- WCBQCUWTZNGFIP-UHFFFAOYSA-N 1-cyclopropyl-3-ethyl-5,6-dimethyl-5-nitro-1,3-diazinane-2,4-dione Chemical compound CC1C(C)([N+]([O-])=O)C(=O)N(CC)C(=O)N1C1CC1 WCBQCUWTZNGFIP-UHFFFAOYSA-N 0.000 description 1
- OTVLVDMONLJOBW-UHFFFAOYSA-N 1-cyclopropyl-5,6-dimethyl-3-(2-methylpropyl)-5-nitro-1,3-diazinane-2,4-dione Chemical compound CC1C(C)([N+]([O-])=O)C(=O)N(CC(C)C)C(=O)N1C1CC1 OTVLVDMONLJOBW-UHFFFAOYSA-N 0.000 description 1
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
- ZUKJMDIXSDYEST-UHFFFAOYSA-N 1-ethyl-5-nitro-6-(1-phenylpyrazol-4-yl)-3-propylpyrimidine-2,4-dione Chemical compound CCN1C(=O)N(CCC)C(=O)C([N+]([O-])=O)=C1C1=CN(C=2C=CC=CC=2)N=C1 ZUKJMDIXSDYEST-UHFFFAOYSA-N 0.000 description 1
- LZEILPQYRNBWFD-UHFFFAOYSA-N 1-ethyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitro-3-propylpyrimidine-2,4-dione Chemical compound CCN1C(=O)N(CCC)C(=O)C([N+]([O-])=O)=C1C1=CN(CC=2C(=CC=CC=2)F)N=C1 LZEILPQYRNBWFD-UHFFFAOYSA-N 0.000 description 1
- MYFZXSOYJVWTBL-UHFFFAOYSA-N 1-methylpyrazole-4-carbaldehyde Chemical compound CN1C=C(C=O)C=N1 MYFZXSOYJVWTBL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PHVRLPFVPVKYOI-UHFFFAOYSA-N 1-phenylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C=NN1C1=CC=CC=C1 PHVRLPFVPVKYOI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- HBJUQLMVCIEESP-UHFFFAOYSA-N 2,5-dihydro-1,2,4-oxadiazole Chemical compound C1NC=NO1 HBJUQLMVCIEESP-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- PZZOEXPDTYIBPI-UHFFFAOYSA-N 2-[[2-(4-hydroxyphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one Chemical compound C1=CC(O)=CC=C1CCNCC1C(=O)C2=CC=CC=C2CC1 PZZOEXPDTYIBPI-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- DFHCXFWCDLBFRZ-UHFFFAOYSA-N 3,6-dimethyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CC(C)CN1C(C)=C([N+]([O-])=O)C(=O)N(C)C1=O DFHCXFWCDLBFRZ-UHFFFAOYSA-N 0.000 description 1
- CFADSIBRSRZBQO-UHFFFAOYSA-N 3,6-dimethyl-1h-pyrimidine-2,4-dione Chemical compound CC1=CC(=O)N(C)C(O)=N1 CFADSIBRSRZBQO-UHFFFAOYSA-N 0.000 description 1
- TWTDBGBBAHKLBT-UHFFFAOYSA-N 3,6-dimethyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CC=1NC(=O)N(C)C(=O)C=1[N+]([O-])=O TWTDBGBBAHKLBT-UHFFFAOYSA-N 0.000 description 1
- BZOBQONVBIUJIG-UHFFFAOYSA-N 3-(2-methoxyethyl)-6-methyl-5-nitro-1-propylpyrimidine-2,4-dione Chemical compound CCCN1C(C)=C([N+]([O-])=O)C(=O)N(CCOC)C1=O BZOBQONVBIUJIG-UHFFFAOYSA-N 0.000 description 1
- YTTVHEKWOMYZFW-UHFFFAOYSA-N 3-(furan-3-ylmethyl)-6-methyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1CC1=COC=C1 YTTVHEKWOMYZFW-UHFFFAOYSA-N 0.000 description 1
- CNGBXLODSCMQLF-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-6-methyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1CC1=CC=C(F)C=C1 CNGBXLODSCMQLF-UHFFFAOYSA-N 0.000 description 1
- OCOGJLZYYKREIY-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1CC1=CC=C(F)C=C1 OCOGJLZYYKREIY-UHFFFAOYSA-N 0.000 description 1
- NXEOXNRFOGQQBA-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methyl]-6-methyl-1h-pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)NC(C)=CC1=O NXEOXNRFOGQQBA-UHFFFAOYSA-N 0.000 description 1
- JUSCYVOYQCDAHU-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methyl]-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C([N+]([O-])=O)=C(C)NC1=O JUSCYVOYQCDAHU-UHFFFAOYSA-N 0.000 description 1
- QQSSKPBIJHMUNX-UHFFFAOYSA-N 3-[fluoro(phenyl)methyl]-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-[(4-methoxyphenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(CC=2C(=CC=CC=2)F)N=C1 QQSSKPBIJHMUNX-UHFFFAOYSA-N 0.000 description 1
- NXXVZNVDWDWLKU-UHFFFAOYSA-N 3-[fluoro(phenyl)methyl]-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-[(4-methoxyphenyl)methyl]-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C(F)C=2C=CC=CC=2)C(=O)C2=C1C=C(C1=CN(CC=3C(=CC=CC=3)F)N=C1)N2 NXXVZNVDWDWLKU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CNZGWEWAMHKLKL-UHFFFAOYSA-N 3-butyl-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O CNZGWEWAMHKLKL-UHFFFAOYSA-N 0.000 description 1
- PVNVFFKJNHFRNO-UHFFFAOYSA-N 3-butyl-1-(1-methoxyethyl)-6-methyl-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C([N+]([O-])=O)=C(C)N(C(C)OC)C1=O PVNVFFKJNHFRNO-UHFFFAOYSA-N 0.000 description 1
- JYFAGJVNOMEYGF-UHFFFAOYSA-N 3-butyl-1-cyclopropyl-5,6-dimethyl-5-nitro-1,3-diazinane-2,4-dione Chemical compound CC1C(C)([N+]([O-])=O)C(=O)N(CCCC)C(=O)N1C1CC1 JYFAGJVNOMEYGF-UHFFFAOYSA-N 0.000 description 1
- VZGWWJBRKINXLH-UHFFFAOYSA-N 3-butyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(1-methoxyethyl)-5-nitropyrimidine-2,4-dione Chemical compound COC(C)N1C(=O)N(CCCC)C(=O)C([N+]([O-])=O)=C1C1=CN(CC=2C(=CC=CC=2)F)N=C1 VZGWWJBRKINXLH-UHFFFAOYSA-N 0.000 description 1
- OGHJMIINFMBEON-UHFFFAOYSA-N 3-butyl-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C([N+]([O-])=O)=C(C)N(CC(C)C)C1=O OGHJMIINFMBEON-UHFFFAOYSA-N 0.000 description 1
- QRGVGZWQHXGOFJ-UHFFFAOYSA-N 3-butyl-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CCCCN1C(=O)C=C(C)NC1=O QRGVGZWQHXGOFJ-UHFFFAOYSA-N 0.000 description 1
- XNEORMFBOGTRLE-UHFFFAOYSA-N 3-butyl-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CCCCN1C(=O)NC(C)=C([N+]([O-])=O)C1=O XNEORMFBOGTRLE-UHFFFAOYSA-N 0.000 description 1
- VCPQEQRHFPJTSN-UHFFFAOYSA-N 3-cyclobutyl-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(C)C(C)=C([N+]([O-])=O)C(=O)N1C1CCC1 VCPQEQRHFPJTSN-UHFFFAOYSA-N 0.000 description 1
- UZQXQHVLRUPKFK-UHFFFAOYSA-N 3-cyclobutyl-1-cyclopropyl-5,6-dimethyl-5-nitro-1,3-diazinane-2,4-dione Chemical compound O=C1N(C2CCC2)C(=O)C([N+]([O-])=O)(C)C(C)N1C1CC1 UZQXQHVLRUPKFK-UHFFFAOYSA-N 0.000 description 1
- XKMRROJXXBMHAJ-UHFFFAOYSA-N 3-cyclobutyl-6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(1-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound C1=2C=C(C3=CN(CC=4C(=CC=CC=4)F)N=C3)NC=2C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 XKMRROJXXBMHAJ-UHFFFAOYSA-N 0.000 description 1
- QFKNUYPFPUAGRO-UHFFFAOYSA-N 3-cyclobutyl-6-methyl-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1C1CCC1 QFKNUYPFPUAGRO-UHFFFAOYSA-N 0.000 description 1
- DKDMASXBYDGTPZ-UHFFFAOYSA-N 3-cyclobutyl-6-methyl-5-nitro-1-(1-phenylethyl)pyrimidine-2,4-dione Chemical compound CC1=C([N+]([O-])=O)C(=O)N(C2CCC2)C(=O)N1C(C)C1=CC=CC=C1 DKDMASXBYDGTPZ-UHFFFAOYSA-N 0.000 description 1
- SPXWSECEOXTYES-UHFFFAOYSA-N 3-cyclobutyl-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1C1CCC1 SPXWSECEOXTYES-UHFFFAOYSA-N 0.000 description 1
- ILUSPSNUTUYRGL-UHFFFAOYSA-N 3-ethyl-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CCN1C(=O)C([N+]([O-])=O)=C(C)N(CC(C)C)C1=O ILUSPSNUTUYRGL-UHFFFAOYSA-N 0.000 description 1
- VWPISPCRFQVXQX-UHFFFAOYSA-N 3-ethyl-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CCN1C(=O)C=C(C)NC1=O VWPISPCRFQVXQX-UHFFFAOYSA-N 0.000 description 1
- NCMSOYCKJGJZKB-UHFFFAOYSA-N 3-ethyl-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CCN1C(=O)NC(C)=C([N+]([O-])=O)C1=O NCMSOYCKJGJZKB-UHFFFAOYSA-N 0.000 description 1
- OVVCUISFVNHUIC-UHFFFAOYSA-N 3-methoxy-1,6-dimethyl-5-nitropyrimidine-2,4-dione Chemical compound CON1C(=O)C([N+]([O-])=O)=C(C)N(C)C1=O OVVCUISFVNHUIC-UHFFFAOYSA-N 0.000 description 1
- QENAXQZVSHKWOP-UHFFFAOYSA-N 3-methoxy-6-methyl-1-(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CON1C(=O)C([N+]([O-])=O)=C(C)N(CC(C)C)C1=O QENAXQZVSHKWOP-UHFFFAOYSA-N 0.000 description 1
- SZHSZJKDZQMRCH-UHFFFAOYSA-N 3-methoxy-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CON1C(=O)C=C(C)NC1=O SZHSZJKDZQMRCH-UHFFFAOYSA-N 0.000 description 1
- YNNIMFMDUDBFBV-UHFFFAOYSA-N 3-methoxy-6-methyl-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CON1C(=O)NC(C)=C([N+]([O-])=O)C1=O YNNIMFMDUDBFBV-UHFFFAOYSA-N 0.000 description 1
- WMTDYEHRRKBVPY-UHFFFAOYSA-N 3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=CNC1=O WMTDYEHRRKBVPY-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- ICENILRKNUKRPB-UHFFFAOYSA-N 5-thiophen-2-yl-1,2-oxazole-3-carbaldehyde Chemical compound O1N=C(C=O)C=C1C1=CC=CS1 ICENILRKNUKRPB-UHFFFAOYSA-N 0.000 description 1
- JGXZJIYPZVRXNP-ZHACJKMWSA-N 6-[(e)-2-(1-benzylpyrazol-4-yl)ethenyl]-5-nitro-1,3-dipropylpyrimidine-2,4-dione Chemical compound O=C1N(CCC)C(=O)N(CCC)C(\C=C\C2=CN(CC=3C=CC=CC=3)N=C2)=C1[N+]([O-])=O JGXZJIYPZVRXNP-ZHACJKMWSA-N 0.000 description 1
- WRAQELHVSDYTGU-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(=O)N(CC(C)C)C(C2=CN(CC=3C(=CC=CC=3)F)N=C2)=C1[N+]([O-])=O WRAQELHVSDYTGU-UHFFFAOYSA-N 0.000 description 1
- GWSXPWAQIOKOMO-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(2-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(CCC=4C=CC=CC=4)C(=O)N(CCC=4C=CC=CC=4)C=3C=2)=C1 GWSXPWAQIOKOMO-UHFFFAOYSA-N 0.000 description 1
- CXFWYCUJFPONGA-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(CC=4C=CN=CC=4)C(=O)N(CC=4C=CN=CC=4)C=3C=2)=C1 CXFWYCUJFPONGA-UHFFFAOYSA-N 0.000 description 1
- LOXKBMGLJGGTGG-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1,3-bis[(4-methoxyphenyl)methyl]-5-nitropyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(CC=2C=CC(OC)=CC=2)C(=O)C([N+]([O-])=O)=C1C1=CN(CC=2C(=CC=CC=2)F)N=C1 LOXKBMGLJGGTGG-UHFFFAOYSA-N 0.000 description 1
- QWXVBMHJAPPSSO-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(2-methylpropyl)-3-(2-phenylethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C=2C=C(C3=CN(CC=4C(=CC=CC=4)F)N=C3)NC=2C(=O)N1CCC1=CC=CC=C1 QWXVBMHJAPPSSO-UHFFFAOYSA-N 0.000 description 1
- CSZAGZVXCRYTTM-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-1-(2-methylpropyl)-5-nitro-3-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound [O-][N+](=O)C=1C(=O)N(CCC=2C=CC=CC=2)C(=O)N(CC(C)C)C=1C(=C1)C=NN1CC1=CC=CC=C1F CSZAGZVXCRYTTM-UHFFFAOYSA-N 0.000 description 1
- DEKUELWDRSVHSP-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(furan-3-ylmethyl)-1-(pyridin-4-ylmethyl)-5h-pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical compound FC1=CC=CC=C1CN1N=CC(C=2NC=3C(=O)N(CC4=COC=C4)C(=O)N(CC=4C=CN=CC=4)C=3C=2)=C1 DEKUELWDRSVHSP-UHFFFAOYSA-N 0.000 description 1
- BUYYEHYZDANIPX-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-3-(furan-3-ylmethyl)-5-nitro-1-(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound C=1C=NC=CC=1CN1C(=O)N(CC2=COC=C2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F BUYYEHYZDANIPX-UHFFFAOYSA-N 0.000 description 1
- FPBGISRCGDPFKI-UHFFFAOYSA-N 6-[1-[(2-fluorophenyl)methyl]pyrazol-4-yl]-5-nitro-1,3-bis(2-phenylethyl)pyrimidine-2,4-dione Chemical compound C=1C=CC=CC=1CCN1C(=O)N(CCC=2C=CC=CC=2)C(=O)C([N+](=O)[O-])=C1C(=C1)C=NN1CC1=CC=CC=C1F FPBGISRCGDPFKI-UHFFFAOYSA-N 0.000 description 1
- QXTPKWUMRQWSKN-UHFFFAOYSA-N 6-methyl-1,3-bis(2-methylpropyl)-5-nitropyrimidine-2,4-dione Chemical compound CC(C)CN1C(C)=C([N+]([O-])=O)C(=O)N(CC(C)C)C1=O QXTPKWUMRQWSKN-UHFFFAOYSA-N 0.000 description 1
- UIIPRHMXBRNECY-UHFFFAOYSA-N 6-methyl-1,3-bis(2-methylpropyl)pyrimidine-2,4-dione Chemical compound CC(C)CN1C(C)=CC(=O)N(CC(C)C)C1=O UIIPRHMXBRNECY-UHFFFAOYSA-N 0.000 description 1
- FVQNFEJKQGWUCI-UHFFFAOYSA-N 6-methyl-1,3-bis(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CCC=2C=CC=CC=2)C(C)=CC(=O)N1CCC1=CC=CC=C1 FVQNFEJKQGWUCI-UHFFFAOYSA-N 0.000 description 1
- JYUJMPFZSQBOAT-UHFFFAOYSA-N 6-methyl-1,3-bis(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CN=CC=2)C(C)=CC(=O)N1CC1=CC=NC=C1 JYUJMPFZSQBOAT-UHFFFAOYSA-N 0.000 description 1
- OQYDYTOYFQIJSY-UHFFFAOYSA-N 6-methyl-1,3-bis[[4-(trifluoromethyl)phenyl]methyl]pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CC(=CC=2)C(F)(F)F)C(C)=CC(=O)N1CC1=CC=C(C(F)(F)F)C=C1 OQYDYTOYFQIJSY-UHFFFAOYSA-N 0.000 description 1
- FNIKOGLKWWBYHD-UHFFFAOYSA-N 6-methyl-1-(2-methylpropyl)-5-nitro-3-(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC(C)C)C(C)=C([N+]([O-])=O)C(=O)N1CCC1=CC=CC=C1 FNIKOGLKWWBYHD-UHFFFAOYSA-N 0.000 description 1
- FMRWAKZUWFOTDM-UHFFFAOYSA-N 6-methyl-3-(2-methylpropyl)-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)C=C(C)NC1=O FMRWAKZUWFOTDM-UHFFFAOYSA-N 0.000 description 1
- ARTLAARPNPCNMT-UHFFFAOYSA-N 6-methyl-3-(2-methylpropyl)-5-nitro-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)NC(C)=C([N+]([O-])=O)C1=O ARTLAARPNPCNMT-UHFFFAOYSA-N 0.000 description 1
- PECQEDXEQILCQR-UHFFFAOYSA-N 6-methyl-3-(2-phenylethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1CCC1=CC=CC=C1 PECQEDXEQILCQR-UHFFFAOYSA-N 0.000 description 1
- LPPDCBVWQDSQGL-UHFFFAOYSA-N 6-methyl-3-(pyridin-4-ylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(C)=CC(=O)N1CC1=CC=NC=C1 LPPDCBVWQDSQGL-UHFFFAOYSA-N 0.000 description 1
- DLVWXMBDUOXIMR-UHFFFAOYSA-N 6-methyl-5-nitro-1,3-bis(2-phenylethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CCC=2C=CC=CC=2)C(C)=C([N+]([O-])=O)C(=O)N1CCC1=CC=CC=C1 DLVWXMBDUOXIMR-UHFFFAOYSA-N 0.000 description 1
- UCADQQLVCUVULT-UHFFFAOYSA-N 6-methyl-5-nitro-1,3-bis(pyridin-4-ylmethyl)pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CN=CC=2)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=NC=C1 UCADQQLVCUVULT-UHFFFAOYSA-N 0.000 description 1
- AHWXWCXUIRGJNQ-UHFFFAOYSA-N 6-methyl-5-nitro-1,3-bis[[4-(trifluoromethyl)phenyl]methyl]pyrimidine-2,4-dione Chemical compound O=C1N(CC=2C=CC(=CC=2)C(F)(F)F)C(C)=C([N+]([O-])=O)C(=O)N1CC1=CC=C(C(F)(F)F)C=C1 AHWXWCXUIRGJNQ-UHFFFAOYSA-N 0.000 description 1
- YPWSNQAQWNMIAP-UHFFFAOYSA-N 6-methyl-5-nitro-3-(2-phenylethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1CCC1=CC=CC=C1 YPWSNQAQWNMIAP-UHFFFAOYSA-N 0.000 description 1
- ZCNBUVAIUWDBSB-UHFFFAOYSA-N 6-methyl-5-nitro-3-(pyridin-4-ylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C([N+]([O-])=O)=C(C)NC(=O)N1CC1=CC=NC=C1 ZCNBUVAIUWDBSB-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- IJLKEYSQISMRCW-UHFFFAOYSA-N C(=C)C1=C(C(NC(N1)=O)=O)[N+](=O)[O-] Chemical compound C(=C)C1=C(C(NC(N1)=O)=O)[N+](=O)[O-] IJLKEYSQISMRCW-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000551547 Dione <red algae> Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PRPVFMPCEJBYSB-UHFFFAOYSA-N [1-[(2-fluorophenyl)methyl]pyrazol-4-yl]methanol Chemical compound C1=C(CO)C=NN1CC1=CC=CC=C1F PRPVFMPCEJBYSB-UHFFFAOYSA-N 0.000 description 1
- KRGBOUIZYVNRTD-UHFFFAOYSA-N [1-[(3-methoxyphenyl)methyl]pyrazol-4-yl]methanol Chemical compound COC1=CC=CC(CN2N=CC(CO)=C2)=C1 KRGBOUIZYVNRTD-UHFFFAOYSA-N 0.000 description 1
- DAAJRPJTFCFXFA-UHFFFAOYSA-N [N+](=O)([O-])C=1C(N(C(N(C=1)CCC)=O)CCC)=O Chemical compound [N+](=O)([O-])C=1C(N(C(N(C=1)CCC)=O)CCC)=O DAAJRPJTFCFXFA-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LLJBCXIAZBDKAQ-UHFFFAOYSA-N ethyl 1-[(2-fluorophenyl)methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC=C1F LLJBCXIAZBDKAQ-UHFFFAOYSA-N 0.000 description 1
- VLDTUZUHFRUZAO-UHFFFAOYSA-N ethyl 1-[(3-fluorophenyl)methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC(F)=C1 VLDTUZUHFRUZAO-UHFFFAOYSA-N 0.000 description 1
- KIRJXENACTYHPR-UHFFFAOYSA-N ethyl 1-[(3-methoxyphenyl)methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC(OC)=C1 KIRJXENACTYHPR-UHFFFAOYSA-N 0.000 description 1
- DVKDDCAIRBMOGF-UHFFFAOYSA-N ethyl 1-[(4-methylphenyl)methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=C(C)C=C1 DVKDDCAIRBMOGF-UHFFFAOYSA-N 0.000 description 1
- PSPLTOAIHPCGJJ-UHFFFAOYSA-N ethyl 1-[[2-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC=C1C(F)(F)F PSPLTOAIHPCGJJ-UHFFFAOYSA-N 0.000 description 1
- MUZVVDZDMRMPPL-UHFFFAOYSA-N ethyl 1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC(C(F)(F)F)=C1 MUZVVDZDMRMPPL-UHFFFAOYSA-N 0.000 description 1
- GXKQVOXCQOQZED-UHFFFAOYSA-N ethyl 1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C)C=1 GXKQVOXCQOQZED-UHFFFAOYSA-N 0.000 description 1
- IIKHONWHFIKUQV-UHFFFAOYSA-N ethyl 1-methylpyrrole-2-carboxylate Chemical compound CCOC(=O)C1=CC=CN1C IIKHONWHFIKUQV-UHFFFAOYSA-N 0.000 description 1
- UBIULDHICQCHJE-UHFFFAOYSA-N ethyl 1-phenylpyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1C1=CC=CC=C1 UBIULDHICQCHJE-UHFFFAOYSA-N 0.000 description 1
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HGUZQMQXAHVIQC-UHFFFAOYSA-N n-methylethenamine Chemical group CNC=C HGUZQMQXAHVIQC-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51601903P | 2003-10-31 | 2003-10-31 | |
| US60/516,019 | 2003-10-31 | ||
| PCT/US2004/035453 WO2005042534A2 (en) | 2003-10-31 | 2004-10-26 | A2b adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004285013A1 true AU2004285013A1 (en) | 2005-05-12 |
Family
ID=34549473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004285013A Abandoned AU2004285013A1 (en) | 2003-10-31 | 2004-10-26 | A2B adenosine receptor antagonists |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7449473B2 (enExample) |
| EP (1) | EP1678181B1 (enExample) |
| JP (1) | JP4863876B2 (enExample) |
| KR (1) | KR20060111467A (enExample) |
| CN (1) | CN1890241A (enExample) |
| AT (1) | ATE419252T1 (enExample) |
| AU (1) | AU2004285013A1 (enExample) |
| BR (1) | BRPI0415888A (enExample) |
| CA (1) | CA2544193C (enExample) |
| DE (1) | DE602004018808D1 (enExample) |
| ES (1) | ES2318363T3 (enExample) |
| MX (1) | MXPA06004789A (enExample) |
| WO (1) | WO2005042534A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| PL1789053T3 (pl) * | 2004-09-01 | 2012-12-31 | Gilead Sciences Inc | Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B |
| EP2311462A1 (en) | 2004-10-15 | 2011-04-20 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| CA2612344A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| CA2644996A1 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| WO2007142577A1 (en) * | 2006-06-05 | 2007-12-13 | Astrazeneca Ab | Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor |
| US7470697B2 (en) * | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
| GB0718432D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| GB0718434D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| TW200938200A (en) * | 2007-12-28 | 2009-09-16 | Dainippon Sumitomo Pharma Co | Methyl-substituted piperidine derivative |
| JP5460690B2 (ja) | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
| EP2306838A4 (en) * | 2008-07-16 | 2011-12-14 | King Pharmaceuticals Res & Dev | METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| BRPI1009398A2 (pt) | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | compostos de pirimidina fundida substituída |
| EP2499142B1 (en) | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| NZ603310A (en) * | 2010-05-21 | 2015-01-30 | Gilead Sciences Inc | Heterocyclic flaviviridae virus inhibitors |
| EP2616470B1 (en) | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| WO2013101598A1 (en) * | 2011-12-27 | 2013-07-04 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2015003881A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| LT4122926T (lt) | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| DE19535504A1 (de) * | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| CA2411013A1 (en) | 2000-06-07 | 2001-12-13 | Jose Manuel Prieto Soto | 6-phenylpyrrolopyrimidinedione derivatives |
| ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| WO2003006465A1 (en) * | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
| US7157440B2 (en) * | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| AU2002359365B2 (en) * | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
-
2004
- 2004-10-26 US US10/973,167 patent/US7449473B2/en not_active Expired - Lifetime
- 2004-10-26 MX MXPA06004789A patent/MXPA06004789A/es unknown
- 2004-10-26 KR KR1020067008426A patent/KR20060111467A/ko not_active Withdrawn
- 2004-10-26 JP JP2006538172A patent/JP4863876B2/ja not_active Expired - Lifetime
- 2004-10-26 DE DE602004018808T patent/DE602004018808D1/de not_active Expired - Lifetime
- 2004-10-26 AU AU2004285013A patent/AU2004285013A1/en not_active Abandoned
- 2004-10-26 CN CNA200480031969XA patent/CN1890241A/zh active Pending
- 2004-10-26 BR BRPI0415888-1A patent/BRPI0415888A/pt not_active Application Discontinuation
- 2004-10-26 AT AT04810023T patent/ATE419252T1/de not_active IP Right Cessation
- 2004-10-26 CA CA2544193A patent/CA2544193C/en not_active Expired - Lifetime
- 2004-10-26 EP EP04810023A patent/EP1678181B1/en not_active Expired - Lifetime
- 2004-10-26 WO PCT/US2004/035453 patent/WO2005042534A2/en not_active Ceased
- 2004-10-26 ES ES04810023T patent/ES2318363T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2544193C (en) | 2012-03-27 |
| ES2318363T3 (es) | 2009-05-01 |
| US20050119287A1 (en) | 2005-06-02 |
| BRPI0415888A (pt) | 2007-01-09 |
| JP4863876B2 (ja) | 2012-01-25 |
| ATE419252T1 (de) | 2009-01-15 |
| EP1678181B1 (en) | 2008-12-31 |
| CN1890241A (zh) | 2007-01-03 |
| US7449473B2 (en) | 2008-11-11 |
| MXPA06004789A (es) | 2006-07-03 |
| WO2005042534A3 (en) | 2005-08-25 |
| DE602004018808D1 (de) | 2009-02-12 |
| EP1678181A2 (en) | 2006-07-12 |
| KR20060111467A (ko) | 2006-10-27 |
| JP2007509947A (ja) | 2007-04-19 |
| CA2544193A1 (en) | 2005-05-12 |
| WO2005042534A2 (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1678181B1 (en) | A2b adenosine receptor antagonists | |
| EP1444233B1 (en) | A2b adenosine receptor antagonists | |
| US8324224B2 (en) | A2B adenosine receptor antagonists | |
| CA2546733C (en) | A2b adenosine receptor antagonists | |
| US20030229106A1 (en) | A2B adenosine receptor antagonists | |
| AU2002359365A1 (en) | A2B adenosine receptor antagonists | |
| AU2003249604B2 (en) | A2B adenosine receptor antagonists | |
| WO2003006465A1 (en) | Partial and full agonist of a adenosine receptors | |
| AU2011224104B2 (en) | A2B adenosine receptor antagonists | |
| HK1092137B (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
| HK1071127B (en) | A2b adenosine receptor antagonists | |
| NZ573577A (en) | Xanthine derivatives as A2B adenosine receptor antagonists suitable for treating conditions such as asthma and diarrhoea | |
| KR20060055453A (ko) | Ａ2ｂ 아데노신 수용체 길항제로서의 크산틴 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |